Commentary
Brodalumab and suicidal ideation in the context of a recent economic crisis in the United States

https://doi.org/10.1016/j.jaad.2015.08.057Get rights and content

References (9)

There are more references available in the full text version of this article.

Cited by (38)

  • Suicidal ideation during COVID-19: The contribution of unique and cumulative stressors

    2022, Psychiatry Research
    Citation Excerpt :

    Suicidal ideation (SI), or the act of contemplating suicidal behaviors, has been shown to increase during acute personal crises (Danesh and Kimball, 2016; Economou et al., 2013; Harmer et al., 2021).

  • Psoriasis in Taiwan: From epidemiology to new treatments

    2018, Dermatologica Sinica
    Citation Excerpt :

    Exacerbation of ulcerative colitis and Crohn's disease in in vitro and in vivo studies reminded prescribers to be cautious when using them in patients with inflammatory bowel diseases.112,113 Suicidal ideation and adverse behavioral events have been reported with brodalumab, an anti-IL-17-receptor antibody and are of significant concern.114–117 Paradoxical exacerbation of psoriasis was caused not only by anti-TNF-α drugs but was also reported in a case report after the switch from infliximab to secukinumab.118

  • Dermatologic Conditions and Risk of Suicide: A Case-Control Study

    2018, Psychosomatics
    Citation Excerpt :

    Patients diagnosed with conditions such as acne, psoriasis, and atopic dermatitis have been identified to have an increased risk of depression and suicidal ideations.12–16 Although there is paucity of data on risk of suicide death with dermatologic conditions, this concern has affected both clinical practice and research.17,18 The ongoing treatment utilization before suicide study, funded by the National Institute of Mental Health, is investigating the association between nonpsychiatric clinical factors such as medical conditions and suicide risk.11

  • IL-17 for therapy

    2017, Journal of Dermatological Science
    Citation Excerpt :

    An unforeseen slight raise in suicide attempts and suicidal ideation was observed in the initial trials performed by Amgen with Brodalumab. Whether this increased suicidal risk is indeed caused by Brodalumab treatment is still under debate [68,69]. For some inflammatory diseases IL-17 neutralization may be contraindicated: Although IL-17 is thought to be implicated in Crohn’s disease, a proof of concept trial in CD using Secukinumab had to be discontinued due to adverse side effects [70].

View all citing articles on Scopus

Funding sources: None.

Disclosure: Dr Kimball has been a consultant and investigator for Amgen, Abbvie, Janssen, Novartis, Celgene, and Pfizer; has been a consultant for Eli Lilly; and has fellowship funding from Janssen. Ms Danesh has no conflicts of interest to declare.

View full text